Lymphoid malignancies
Drug research and approvals for lymphoid malignancies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 624 studies of lymphoid malignancies are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 624
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 624 recruiting on ClinicalTrials.gov ↗
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic LeukaemiaNCT07940920 · Not applicable · University of Surrey · starts Dec 1, 2026
- Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology PatientsNCT07938333 · Not reported · Children's Hospital of Orange County · starts Nov 9, 2026
- Feasibility and Acceptability of Remote Saliva CollectionNCT07884474 · Not reported · St. Jude Children's Research Hospital · starts Dec 1, 2026
- Ph+ ALL in Chinese Children: Diagnosis, Treatment, and SurvivalNCT07813208 · Not reported · The Children's Hospital of Zhejiang University School of Medicine · starts Aug 1, 2025
- Nurture by Nature Feasibility StudyNCT07780123 · Not applicable · Ina Olmer Specht · starts Oct 1, 2026
- Ibrutinib Plus Venetoclax Long-Term Outcomes in CLLNCT07774390 · Not reported · European Research Initiative on CLL · starts Dec 18, 2025
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsNCT07763054 · Not reported · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · starts Aug 1, 2025
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
Newest first; search them all in Canada trials
| Feb 22, 2023 | An open-label, phase 1/2 study evaluating AVM0703 in patients with lymphoid malignancies (opal study)Dexamethasone (avm 0703) | Avm Biotechnology, LLC | Pending |
| Nov 29, 2018 | A phase 2, open-label, monotherapy, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1…Pemigatinib (INCB054828) | Incyte | Closed |
| Apr 29, 2016 | A phase 1, dose-escalation/dose-expansion study evaluating the safety, pharmacokinetics, and pharmacodynamic effects of orally administered CB-5083 in subjects…CB-5083 | Cleave Biosciences | Ongoing |
| Jan 15, 2016 | A phase I/II study of pembrolizumab (MK-3475) in children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma…Keytruda | Merck & Co. (MSD) | Ongoing |
| Jun 13, 2014 | A phase I study evaluating safety, tolerability and pharmacokinetics of escalating doses of AGS67E given as monotherapy in subjects with refractory or relapsed…AGS67E | Astellas Pharma | Closed |
| Dec 12, 2013 | A phase 1b study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of gs 9820 monotherapy and combination therapy in subjects…GS-9820 /rituximab | Gilead Sciences | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA